BA
PGNX

BKS Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

BKS Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$550K Buy
118,587
+5,102
+4% +$23.1K 0.22% 110
2018
Q4 		$477K Sell
113,485
-1,630
-1% -$8.3K 0.22% 115
2018
Q3 		$721K Sell
115,115
-10,000
-8% -$76.8K 0.26% 98
2018
Q2 		$1.01M Hold
125,115
– – 0.36% 73
2018
Q1 		$933K Sell
125,115
-10,000
-7% -$66.5K 0.34% 76
2017
Q4 		$804K Sell
135,115
-10,000
-7% -$60.8K 0.29% 82
2017
Q3 		$1.07M Hold
145,115
– – 0.41% 68
2017
Q2 		$985K Buy
145,115
+37,915
+35% +$280K 0.4% 72
2017
Q1 		$1.01M Hold
107,200
– – 0.44% 65
2016
Q4 		$926K Sell
107,200
-135,450
-56% -$1M 0.44% 71
2016
Q3 		$1.54M Sell
242,650
-10,000
-4% -$60.5K 0.71% 50
2016
Q2 		$1.07M Sell
252,650
-30,000
-11% -$145K 0.55% 59
2016
Q1 		$1.23M Sell
282,650
-8,500
-3% -$37.9K 0.64% 55
2015
Q4 		$1.78M Hold
291,150
– – 0.92% 40
2015
Q3 		$1.67M Hold
291,150
– – 0.93% 38
2015
Q2 		$2.17M Hold
291,150
– – 1.04% 36
2015
Q1 		$1.74M Buy
+291,150
New +$1.83M 0.83% 42

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BKS Advisors's PGNX Position: Q1 2019 in Review

BKS Advisors increased its Progenics Pharmaceuticals Inc (PGNX) stake by 4.5% in Q1 2019, buying an estimated $23.1K and bringing the position to 118,587 shares worth $550K. The position accounts for 0.22% of the portfolio, ranked #110.

BKS Advisors first reported a position in PGNX in Q1 2015 and has held it in 17 quarters since. The position peaked at $2.17M in Q2 2015. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • BKS Advisors held 118,587 shares of Progenics Pharmaceuticals Inc worth $550K as of Q1 2019.
  • BKS Advisors bought 5,102 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $23.1K.
  • Progenics Pharmaceuticals Inc made up 0.22% of BKS Advisors's portfolio in Q1 2019, its #110 holding.
  • BKS Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and has held it in 17 quarters since.
  • BKS Advisors's Progenics Pharmaceuticals Inc position peaked at $2.17M in Q2 2015.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on BKS Advisors's 13F filing for Q1 2019, filed 16 Apr 2019.